Edison, NJ, United States of America

Yuanzheng Zhang

This inventor holds 23 USPTO granted patents and 14 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Canine Antibody Therapy. Top assignee: Intervet Inc.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuanzheng Zhang. Retrieved from https://idiyas.com/inventor/yuanzheng-zhang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23 

% Patents Active = 95.7

 

 

Average Co-Inventor Count = 3.0

ph-index = 4

Forward Citations = 28(Granted Patents)


Location History:

  • Elkhorn, NE (US) (2014)
  • Somerset, NJ (US) (2022)
  • Edison, NJ (US) (2018 - 2023)

Company Filing History:


Years Active: 2014-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Caninized Antibodies
Bispecific Antibodies
Atopic Dermatitis
Canine Interleukin-31
Canine Interleukin-4
CTLA-4 Antibodies
PD-1 Antibodies
PD-L1 Antibodies
Binding Partners
Therapeutics
Canine Immunology
Receptor Alpha
23 patents (USPTO):Explore Patents

Title: The Innovations of Yuanzheng Zhang

Introduction

Yuanzheng Zhang is a prominent inventor based in Edison, NJ (US). He has made significant contributions to the field of veterinary medicine, particularly in the development of caninized antibodies for the treatment of cancer in canines and other companion animals. With a total of 23 patents to his name, Zhang's work is paving the way for innovative therapies in veterinary oncology.

Latest Patents

One of Zhang's latest patents is focused on caninized antibodies against canine CTLA-4. This invention provides caninized murine antibodies that possess specific sequences and a high binding affinity for canine CTLA-4. Additionally, it includes the identification of epitopes of canine CTLA-4 for these antibodies. The invention also discusses the application of these antibodies in treating cancer in canines and other companion animals. Another notable patent involves caninized antibodies against canine PD-1, which also exhibit a high binding affinity for the target. This invention further emphasizes the use of these caninized antibodies in cancer treatment for dogs.

Career Highlights

Yuanzheng Zhang has established himself as a key figure in the field of veterinary therapeutics. His work at Intervet Inc. has allowed him to focus on developing innovative solutions that address critical health issues in companion animals. His research and inventions are instrumental in advancing veterinary medicine.

Collaborations

Zhang has collaborated with notable colleagues, including Mohamad A Morsey and Ian Tarpey. These partnerships have contributed to the success of his research and the development of his patents.

Conclusion

Yuanzheng Zhang's contributions to veterinary medicine through his innovative patents are making a significant impact in the treatment of cancer in canines. His work exemplifies the importance of research and innovation in improving the health and well-being of companion animals.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…